Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in children and adults, helping to reduce airway inflammation and improve breathing.

GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains and responsive technical support.

Montelukast is a leukotriene receptor antagonist used to treat respiratory allergic conditions. - Asthma: improves control of persistent asthma and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Headache: mild to moderate headache. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: mild stomach discomfort. - Cough: occasional dry cough.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Assess asthma control: confirm that the patient’s asthma is not uncontrolled before initiating therapy. - Monitor for neuropsychiatric symptoms: observe for mood changes, depression, or suicidal ideation. - Review concomitant medications: evaluate potential drug interactions, especially with CYP450 modulators. - Use in pediatric patients: follow age‑specific dosing recommendations and monitor growth. - Pregnancy and lactation: weigh potential benefits against unknown risks; consult current guidelines. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: drugs such as rifampin or carbamazepine may reduce Montelukast plasma levels. - Phenobarbital: may decrease therapeutic effect.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole): may increase Montelukast concentrations. - Warfarin: potential for altered anticoagulant effect; monitor INR. - Beta‑agonists: additive bronchodilation effect; monitor for excessive bronchodilation.